Description: BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Home Page: www.bergenbio.com
Jonas Lies vei 91
Bergen,
5009
Norway
Phone:
47 55 96 11 59
Officers
| Name | Title |
|---|---|
| Mr. Martin Olin | Chief Exec. Officer |
| Mr. Rune Skeie | Chief Financial Officer |
| Dr. James Barnes Ph.D. | Chief Operating Officer |
| Dr. Nigel McCracken M.Sc., Ph.D. | Chief Scientific Officer |
| Ms. Debbie Molyneux | Chief People Officer |
| Ms. Gayle M. Mills M.B.A | Chief Bus. Officer |
| Ms. Cristina Oliva M.D. | Chief Medical Officer |
| Dr. Alison Messom | Director of Clinical Operations |
| Dr. Akil Jackson | Medical Director |
Exchange: OL
Country: NO
Currency: Norwegian Krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.9196 |
| Price-to-Sales TTM: | 756.5925 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 34 |